- General
- Technology
- Applications
- Partnerships
- Press
- Contact
Our Mission
Leadership
Scientific Advisory Board
Brain Circle
Awards & Honors
Leadership
Scientific Advisory Board
Brain Circle
Awards & Honors
SPEARS Algorithm
iBrain Device
iBrain Device
CONSULTANTS
Ms. Tracy Dixon-Salazar is a PhD Candidate in the highly-ranked Neuroscience program at UCSD. She is an accomplished molecular geneticist, cell biologist and biochemist, and a training electrophysiologist in the lab of Dr. Lisa Boulanger. Her thesis research employs a variety of techniques to reveal the mechanisms by which immune system molecules regulate normal synaptic function in the CNS. She is a recipient of the prestigious NSF Graduate Research Fellowship for this work. In previous research, Ms. Dixon-Salazar was part of the team that identified the first causative gene mutations for human Joubert Syndrome; a finding that has had significant clinical impact. She holds a Bachelor of Science degree in Physiology and Neuroscience and has a special interest in the neural mechanisms of epilepsy and synchrony. She also serves on the Research Board for the epilepsy organization CURE, and is a member of the Board of Directors for the Epilepsy Alliance of Orange County. Ms. Dixon-Salazar will help NeuroVigil create an epilepsy funding and research program.
Dr. Luca Finelli is Head for Neuroscience and Ophthalmics, M&S, Novartis Pharma AG at Novartis Headquarters in Basel, Switzerland. He specializes in modeling & simulation (M&S) strategy for drug discovery and development, with special emphasis on Alzheimer's disease, Parkinson's disease, Epilepsy, Depression, Migraine, Attention deficit disorder and Schizophrenia. Dr. Finelli collected more than 10 years experience in computational modeling, biostatistics, signal analysis and functional imaging with application to sleep research, pharmacology, disease modeling and neuroscience. Luca holds a Ph.D in Neuroscience/Physics and a MS in Theoretical Physics from the Swiss Federal Institute of Technology in Zurich. In Zurich, Dr. Finelli wrote a thesis on the effects of sleep deprivation in humans in Dr. Alexander Borbely's laboratory. He then spent four years working on neural coding and brain imaging as a postdoctoral fellow in Dr. Sejnowski's Computational Neurobiology Laboratory at the Salk Institute in La Jolla, California.
Dr. Mary Ellen Kitler is a Fellow of the American College of Clinical Pharmacology and a Fellow of the Society of Geriatric Cardiology. She worked for over 20 years in the pharmaceutical industry at Sandoz and Zyma (daughter company of Ciba-Geigy) in research and development where she directed international human clinical trials and was a statistical liaison for these trials. At the World Health Organization (WHO), Dr. Kitler spent many years within various depts., such as malaria, tuberculosis, drug management policy and influenza. Dr. Kitler served as first executive officer for the WHO initiative, New Medicines for Malaria Venture. While at WHO, she developed the strategy for implementation of fixed dose combination for the treatment of tuberculosis. This strategy is now being used in the global program, “STOP TB”. Dr. Kitler has accrued experience in many public health issues, including Bioterrorism. She is a Johns Hopkins and Oxford trained biostatistician. Dr. Kitler will help NeuroVigil with grant writing and clinical trials.
Sir Harold Kroto has been an active researcher for most of his career. In 1996 he was knighted for his contributions to chemistry, and later that year won the Nobel Prize for Chemistry for the discovery of the C60 Buckminsterfullerene, a new form of carbon. His is chairman of the board of the Vega Science Trust, which produces science programmes for network television, and is a Royal Society Research Professor at the Univeristy of Sussex and the Francis Eppes Professor in the department of Chemistry at the Florida State University. In 2001, Sir Harold won the Royal Society's prestigious Michael Faraday Award. The award is given annually to a scientist who has done the most to further public communication of science, engineering or technology in the United Kingdom. Besides his many interests, Harry is an inventive graphic designer (he is creating NeuroVigil's logo).
Dr. Robert Mittendorff graduated with his MD and MBA from Harvard Medical School and Harvard Business School, respectively and has experience in clinical medicine, venture backed startups, strategy consulting, and neuroscience research. He has trained in emergency medicine at Stanford, where he designed and pursued approval of an IRB backed device trial, and was involved in several prior venture backed startups including Phylogix, Inc. where he worked in general management, business development activities, and authored the company's first operating plan. He has also consulted in R&D and operations strategy at Merck & Co., Inc. and at the Boston Consulting Group. While a medical student, he was awarded a Howard Hughes Fellowship and pursued neuroscience and neuroengineering sleep research at both MIT and Harvard Medical School. He holds a B.S. from Johns Hopkins in Biomedical Engineering. Robert has been instrumental in formulating NV's business plan.
Dr. Howard Morgan began working with Idealab in 1996 and serves on their board. Howard is also co-founder and partner in First Round Capital, a seed stage venture capital investment firm specializing in the areas of computer and communications technologies and President of the Arca Group Inc.. He has more than 25 years of experience with more than thirty high-tech entrepreneurial ventures. Howard was Professor of Decision Sciences at the Wharton School of the University of Pennsylvania and Professor of Computer Science at the Moore School at the University of Pennsylvania for almost 15 years. He serves on the boards of a number of companies and is a respected author. He received the Entrepreneur of the Year Award in 1997. Howard received his Ph.D. in operations research from Cornell University and his B.S. from the City University of New York.
Dr. Kary Mullis received a Bachelor of Science degree in Chemistry from the Georgia Institute of Technology in 1966. He earned a Ph.D. degree in Biochemistry from the University of California, Berkeley, in 1972. Dr. Mullis joined the Cetus Corp. in Emeryville, California, as a DNA chemist in 1979. During his seven years there, he conducted research on oligonucleotide synthesis and invented the polymerase chain reaction, for which he won the 1993 Nobel Prize in Chemistry. The process, which Dr. Mullis conceptualized in 1983, is hailed as one of the monumental scientific techniques of the twentieth century. A method of amplifying DNA, PCR multiplies a single, microscopic strand of the genetic material billions of times within hours. The process has multiple applications in medicine, genetics, biotechnology and forensics.
Dr. Thomas J. Sullivan worked several years as an analog integrated circuit designer for Burr-Brown Corporation in Tucson, Arizona. He earned a Ph.D. in Electrical Engineering and Cognitive Science from the University of California, San Diego in 2006. His areas of expertise include analog circuit design and theoretical models of the human brain's visual system. He is currently working at a startup company called NeuroSky, bringing EEG technology to toys, video games, and various other consumer applications.
Dr. Renate Wehrle's scientific carrier involves both the transportation industry and sleep research. Dr. Wehrle's master thesis, in Commercial Information Technology, at the University of Regensburg was: “Development and Evaluation of a User Interface for an Automatic Car Park“(BMW funded research project). At the Max-Planck Institute in Munich, Dr. Wehrle wrote a PhD thesis entitled “Functional Neuroanatomy of the Sleeping Brain: Insights from combining fMRI and EEG“. She has focused extensively on REM sleep and neural correlates of lucid dreaming. As of January 2008, Dr. Wehrle is conducting sleep research at ETH and the University of Zurich. She is a long-time collaborator of Dr. Low's. Dr. Wehrle will assist NeuroVigil in the development of a core sleep research facility in Munich.
Ms. Tracy Dixon-Salazar is a PhD Candidate in the highly-ranked Neuroscience program at UCSD. She is an accomplished molecular geneticist, cell biologist and biochemist, and a training electrophysiologist in the lab of Dr. Lisa Boulanger. Her thesis research employs a variety of techniques to reveal the mechanisms by which immune system molecules regulate normal synaptic function in the CNS. She is a recipient of the prestigious NSF Graduate Research Fellowship for this work. In previous research, Ms. Dixon-Salazar was part of the team that identified the first causative gene mutations for human Joubert Syndrome; a finding that has had significant clinical impact. She holds a Bachelor of Science degree in Physiology and Neuroscience and has a special interest in the neural mechanisms of epilepsy and synchrony. She also serves on the Research Board for the epilepsy organization CURE, and is a member of the Board of Directors for the Epilepsy Alliance of Orange County. Ms. Dixon-Salazar will help NeuroVigil create an epilepsy funding and research program.
Dr. Luca Finelli is Head for Neuroscience and Ophthalmics, M&S, Novartis Pharma AG at Novartis Headquarters in Basel, Switzerland. He specializes in modeling & simulation (M&S) strategy for drug discovery and development, with special emphasis on Alzheimer's disease, Parkinson's disease, Epilepsy, Depression, Migraine, Attention deficit disorder and Schizophrenia. Dr. Finelli collected more than 10 years experience in computational modeling, biostatistics, signal analysis and functional imaging with application to sleep research, pharmacology, disease modeling and neuroscience. Luca holds a Ph.D in Neuroscience/Physics and a MS in Theoretical Physics from the Swiss Federal Institute of Technology in Zurich. In Zurich, Dr. Finelli wrote a thesis on the effects of sleep deprivation in humans in Dr. Alexander Borbely's laboratory. He then spent four years working on neural coding and brain imaging as a postdoctoral fellow in Dr. Sejnowski's Computational Neurobiology Laboratory at the Salk Institute in La Jolla, California.
Dr. Mary Ellen Kitler is a Fellow of the American College of Clinical Pharmacology and a Fellow of the Society of Geriatric Cardiology. She worked for over 20 years in the pharmaceutical industry at Sandoz and Zyma (daughter company of Ciba-Geigy) in research and development where she directed international human clinical trials and was a statistical liaison for these trials. At the World Health Organization (WHO), Dr. Kitler spent many years within various depts., such as malaria, tuberculosis, drug management policy and influenza. Dr. Kitler served as first executive officer for the WHO initiative, New Medicines for Malaria Venture. While at WHO, she developed the strategy for implementation of fixed dose combination for the treatment of tuberculosis. This strategy is now being used in the global program, “STOP TB”. Dr. Kitler has accrued experience in many public health issues, including Bioterrorism. She is a Johns Hopkins and Oxford trained biostatistician. Dr. Kitler will help NeuroVigil with grant writing and clinical trials.
Sir Harold Kroto has been an active researcher for most of his career. In 1996 he was knighted for his contributions to chemistry, and later that year won the Nobel Prize for Chemistry for the discovery of the C60 Buckminsterfullerene, a new form of carbon. His is chairman of the board of the Vega Science Trust, which produces science programmes for network television, and is a Royal Society Research Professor at the Univeristy of Sussex and the Francis Eppes Professor in the department of Chemistry at the Florida State University. In 2001, Sir Harold won the Royal Society's prestigious Michael Faraday Award. The award is given annually to a scientist who has done the most to further public communication of science, engineering or technology in the United Kingdom. Besides his many interests, Harry is an inventive graphic designer (he is creating NeuroVigil's logo).
Dr. Robert Mittendorff graduated with his MD and MBA from Harvard Medical School and Harvard Business School, respectively and has experience in clinical medicine, venture backed startups, strategy consulting, and neuroscience research. He has trained in emergency medicine at Stanford, where he designed and pursued approval of an IRB backed device trial, and was involved in several prior venture backed startups including Phylogix, Inc. where he worked in general management, business development activities, and authored the company's first operating plan. He has also consulted in R&D and operations strategy at Merck & Co., Inc. and at the Boston Consulting Group. While a medical student, he was awarded a Howard Hughes Fellowship and pursued neuroscience and neuroengineering sleep research at both MIT and Harvard Medical School. He holds a B.S. from Johns Hopkins in Biomedical Engineering. Robert has been instrumental in formulating NV's business plan.
Dr. Howard Morgan began working with Idealab in 1996 and serves on their board. Howard is also co-founder and partner in First Round Capital, a seed stage venture capital investment firm specializing in the areas of computer and communications technologies and President of the Arca Group Inc.. He has more than 25 years of experience with more than thirty high-tech entrepreneurial ventures. Howard was Professor of Decision Sciences at the Wharton School of the University of Pennsylvania and Professor of Computer Science at the Moore School at the University of Pennsylvania for almost 15 years. He serves on the boards of a number of companies and is a respected author. He received the Entrepreneur of the Year Award in 1997. Howard received his Ph.D. in operations research from Cornell University and his B.S. from the City University of New York.
Dr. Kary Mullis received a Bachelor of Science degree in Chemistry from the Georgia Institute of Technology in 1966. He earned a Ph.D. degree in Biochemistry from the University of California, Berkeley, in 1972. Dr. Mullis joined the Cetus Corp. in Emeryville, California, as a DNA chemist in 1979. During his seven years there, he conducted research on oligonucleotide synthesis and invented the polymerase chain reaction, for which he won the 1993 Nobel Prize in Chemistry. The process, which Dr. Mullis conceptualized in 1983, is hailed as one of the monumental scientific techniques of the twentieth century. A method of amplifying DNA, PCR multiplies a single, microscopic strand of the genetic material billions of times within hours. The process has multiple applications in medicine, genetics, biotechnology and forensics.
Dr. Thomas J. Sullivan worked several years as an analog integrated circuit designer for Burr-Brown Corporation in Tucson, Arizona. He earned a Ph.D. in Electrical Engineering and Cognitive Science from the University of California, San Diego in 2006. His areas of expertise include analog circuit design and theoretical models of the human brain's visual system. He is currently working at a startup company called NeuroSky, bringing EEG technology to toys, video games, and various other consumer applications.
Dr. Renate Wehrle's scientific carrier involves both the transportation industry and sleep research. Dr. Wehrle's master thesis, in Commercial Information Technology, at the University of Regensburg was: “Development and Evaluation of a User Interface for an Automatic Car Park“(BMW funded research project). At the Max-Planck Institute in Munich, Dr. Wehrle wrote a PhD thesis entitled “Functional Neuroanatomy of the Sleeping Brain: Insights from combining fMRI and EEG“. She has focused extensively on REM sleep and neural correlates of lucid dreaming. As of January 2008, Dr. Wehrle is conducting sleep research at ETH and the University of Zurich. She is a long-time collaborator of Dr. Low's. Dr. Wehrle will assist NeuroVigil in the development of a core sleep research facility in Munich.